Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Koe Jan	2. Issuer Name and Ticker or Trading Symbol PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle) 1204 E. CENTRAL ROAD,, SUITE 100	3. Date of Earliest Transaction (MM/DD/YYYY) 3/29/2016
(Street) ARLINGTON HEIGHTS, IL 60005 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	3/29/2016		O ⁽¹⁾		100000	A	$1.25 ⁽¹⁾	686300	D
Common Stock	3/29/2016		O ⁽¹⁾		100000	A	$1.25 ⁽¹⁾	786300	D
Common Stock								150000	I	By Vekoe Partners LLC

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock Warrants (right to buy)	$1.25 ⁽¹⁾	3/29/2016		O ⁽¹⁾			100000	6/28/2012	4/15/2016	Common Stock	100000	⁽¹⁾	0	D
Common Stock Warrants (right to buy)	$0.85	3/29/2016		O ⁽¹⁾		100000		3/29/2016	6/19/2020	Common Stock	100000	⁽¹⁾	100000	D
Common Stock Warrants (right to buy)	$1.25 ⁽¹⁾	3/29/2016		O ⁽¹⁾			100000	4/20/2011	4/20/2016	Common Stock	100000	⁽¹⁾	0	D
Common Stock Warrants (right to buy)	$0.85	3/29/2016		O ⁽¹⁾		100000		3/29/2016	6/19/2020	Common Stock	100000	⁽¹⁾	100000	D

Explanation of Responses:

( 1)

On March 29, 2016, the reporting person exercised an aggregate of 200,000 warrants pursuant to the Issuer's warrant exchange offer, at a discounted exercise price of $0.50 per share, which exercise consisted of: (i) an exercise of 100,000 shares pursuant to a warrant issued on June 28, 2012, with an original exercise price of $1.25 per share and (ii) an exercise of 100,000 shares pursuant to a warrant issued on September 20, 2013, with an original exercise price of $1.25 per share. Under the terms of the warrant exchange offer, holders received, in addition to the common stock acquired upon exercise of their existing warrants, an equal number of new warrants to purchase the same number of shares of the Issuer's common stock at an exercise price of $0.85 per share that will expire June 19, 2020.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Koe Jan 1204 E. CENTRAL ROAD, SUITE 100 ARLINGTON HEIGHTS, IL 60005	X

Signatures
/s/ Jan E. Koe		3/31/2016
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.